Treats hypertension. Sold as Micardis Hct. Every FDA application for this active ingredient: 1 branded and 10 generic.
As of Nov 15, 2026, FDA lists 11 applications for Hydrochlorothiazide; Telmisartan (sold as Micardis Hct), first approved Nov 17, 2000, with 0 new uses approved and 0 published complete response letters.
| Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential HypertensionHypertension (HTN), Low-Renin Essential Hypertension · China National Center for Cardiovascular Diseases | Phase 4 | Not yet recruiting | Nov 12, 2026 |
| Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential HypertensionEssential Hypertension · Yuhan Corporation | Phase 4 | Active, not recruiting | Sep 18, 2023 |
| Nov 17, 2000 | Micardis HctNDA 21162 · New combination | Boehringer Ingelheim | 15 | Marketed |
| Feb 25, 2014 | Telmisartan And HydrochlorothiazideANDA 91648 | Natco | 1 | Discontinued |
| Feb 25, 2014 | Telmisartan And HydrochlorothiazideANDA 201192 | Torrent | 3 | Discontinued |
| Feb 25, 2014 | Telmisartan And HydrochlorothiazideANDA 203010 | Alembic | 6 | Marketed |
| Aug 7, 2014 | Telmisartan And HydrochlorothiazideANDA 91351 | Lupin | 5 | Discontinued |
| Nov 2, 2015 | Telmisartan And HydrochlorothiazideANDA 204169 | Macleods Pharms | 5 | Discontinued |
| Dec 15, 2016 | Telmisartan And HydrochlorothiazideANDA 208727 | Aurobindo Pharma | 3 | Marketed |
| Aug 15, 2017 | Telmisartan And HydrochlorothiazideANDA 204221 | Zydus Pharms | 2 | Marketed |
| Nov 6, 2017 | Telmisartan And HydrochlorothiazideANDA 209028 | Prinston | 4 | Marketed |
| Mar 4, 2019 | Telmisartan And HydrochlorothiazideANDA 202544 | Glenmark Pharms Ltd | 2 | Marketed |
| Mar 3, 2025 | Telmisartan And HydrochlorothiazideANDA 218406 | Mankind Pharma | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA